Colder Drugs Will Prevail - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Colder Drugs Will Prevail
An expanding number of products and services plug gaps in the cold chain. This article contains bonus online-exclusive material.

Pharmaceutical Technology
Volume 33, Issue 8

Hallie Forcinio
Pharmaceutical companies that make temperature-sensitive products pay a lot of attention to the cold chain, which protects products until they reach their points of use. Until recently, manufacturers relied on insulated shippers based on foam and gel packs or dry ice. These designs rely on convection to cool and maintain the temperature of the air around the product.

Today, pharmaceutical companies are looking for longer periods of protection, and a growing number of protective packaging designs rely on conduction. In these packages, phase-change materials keep the product in the right temperature range for the required amount of time despite ambient conditions.

We will be seeing more ...
Traditional "expanded polystyrene-foam shippers with water-based gel packs may still work in certain applications, but there's been a tremendous improvement in the ability to control temperature," says Eric Lindquist, president of Entropy Solutions (Minneapolis), a supplier of temperature-controlled packaging.

The envelope portion of the Greenbox Inflator Pack is suitable for one round trip before being recycled. The interior Puretemp phase-change panels can be reused dozens of times. (IMAGE IS COURTESY OF ENTROPY SOLUTIONS)
Shippers based on conductive phase-change materials typically offer several advantages over traditional packages: a smaller size, lighter weight, more consistent temperature readings from top to bottom, and a longer period of protection. In addition, these shippers are recyclable and can be used for hundreds, if not thousands, of trips. Although more expensive, shippers based on conduction often generate cost savings, particularly if their design permits a holding period that allows manufacturers to switch from overnight air delivery to two-day or ground delivery.

The Greenbox Pallet Shipper withstands at least 250 trips. (IMAGE IS COURTESY OF ENTROPY SOLUTIONS)
"Many companies with temperature-sensitive products don't ship on Fridays because there is no one at the destination to receive it until Monday," reports Karl Schlenker, vice-president of business development for Minnesota Thermal Science (MTS, Baxter, MN), another supplier of temperature-controlled packaging. With 72- or 96-h shippers, "companies can ship on Fridays, too," he explains.

Cold-chain monitoring options from Cortegra include reusable, flexible sensors with a pressure-sensitive back. (IMAGE IS COURTESY OF CORTEGRA)
Solstice Neurosciences (Malvern, PA) relies on a custom thermal box. The passive system incorporates proprietary high-performance insulation that offers an R-value of 45 per inch of thickness. The design not only maintains its payload at the required temperature for the required time, but also simplifies loading (AcuTemp shipper with ThermoCor insulating panels, AcuTemp Thermal Systems, Dayton, OH).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here